News

Benefits of Combining Olopatadine and Mometasone in the Treatment of Allergic Rhinitis
Ryaltris is indicated for adults and adolescents aged 12 years and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis (AR). The active ingredient of the preparation is a fixed combination of locally acting antihistamine olopatadine hydrochloride and corticosteroid mometasone furoate. Its efficacy and safety have been confirmed by numerous clinical studies, compared to placebo, as well as other drugs used in the treatment of AR.

Efficacy and Safety of Fixed Combination of Olopatadine and Mometasone in Nasal Spray for Treatment of Seasonal Allergic Rhinitis
Patients with allergic rhinitis require medications with rapid onset and long duration of action.…

Luck in Unluckiness: Influence of Anticoagulant Therapy on Severity of Stroke in Atrial Fibrillation
A recent Swiss study evaluated the severity, complications, and outcomes of cerebrovascular…

Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure
The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing…

New Drug in the Biologic Therapy Arsenal for Plaque Psoriasis
Bimekizumab shows promising effects in clinical studies with psoriasis patients. Let's take a…

Ceftaroline vs. Vancomycin in the Treatment of Acute Pulmonary Exacerbation of Cystic Fibrosis
Up to 25% of patients with cystic fibrosis are colonized with methicillin-resistant Staphylococcus…

Safety of Long-Term Therapy with Bevacizumab in Oncological Patients
The angiogenesis inhibitor bevacizumab is typically administered long-term. Therefore, a study…

Effectiveness of Idarucizumab Reversal Effect
It is, of course, a great advantage if doctors have a specific substance available that counteracts…

Pain Management After Day Surgery
Effective pain control is a crucial part of recovery for patients after painful surgical…

Venetoclax Treatment Strategies in Patients with CLL
One of the new targeted preparations in the treatment of chronic lymphocytic leukemia (CLL) is the…